Singapore surrogacy: medical and donor requirements
The short answer
Singapore’s assisted-reproduction rules regulate licensed clinical services, but they do not create a simple checklist that makes a surrogacy arrangement lawful. One important obstacle is regulation 36(a) of the Healthcare Services (Assisted Reproduction Service) Regulations 2023: a licensee must not transfer an embryo into a woman who intends to give the child up for adoption. In a conventional surrogacy arrangement, the carrier is usually expected to hand the child to the intended parent or parents, so the provision raises a direct and serious legal issue. Do not assume that calling the arrangement something other than adoption resolves it.
Regulations 31 and 37 may create independent barriers as well: the carrier is ordinarily the patient for transfer, so her eligibility, marital status and the source of the gametes must be assessed separately.
Which rules apply
The main clinical source is the Healthcare Services (Assisted Reproduction Service) Regulations 2023, made under the Healthcare Services Act 2020. They came into operation on 26 June 2023 and were amended with effect from 18 December 2023. The official legislation listing showed a current-version date of 22 October 2026 in indexed search text, but direct retrieval of the full legislation page returned an access error. The rules govern Singapore licensees providing assisted-reproduction services, including collection and screening of reproductive cells, handling and storage, embryo creation and embryo transfer. They are not a ruling on what an overseas clinic may do or on who will be recognised as a child’s legal parent.
The surrogacy-specific barrier
Regulation 36(a) is worded as a prohibition on the licensed provider’s conduct: the licensee must not transfer an embryo into the body of a woman who intends to give the child up for adoption. The text does not, by itself, decide every possible question about private conduct, a foreign treatment cycle, the enforceability of a contract or later parentage recognition. But it makes an embryo transfer in a conventional Singapore-based surrogacy plan unsafe to assume permissible. Before paying, starting medication or arranging a transfer, obtain a written Singapore-law opinion addressing the exact intended arrangement and the carrier’s intended post-birth actions. Regulation 36(a) does not expressly use the word “surrogacy”; its application depends on the facts and the intended post-birth legal route, including whether the carrier is intended to give the child up for adoption. A contract or different label alone does not resolve that question.
Clinical eligibility and safety
For a procedure other than elective oocyte storage, regulation 31 requires the licensed provider to be satisfied that the procedure can be carried out safely, based on the view of a qualified assisted-reproduction practitioner. The patient must also be over 35, or be 35 or younger with medical indications for the procedure. Here, “patient” means the woman receiving the relevant clinical procedure; in a proposed gestational-carrier arrangement, that would ordinarily be the carrier for embryo transfer. Meeting the age or medical-indication condition is not a guarantee of treatment: the practitioner must still consider safety, and other legal restrictions continue to apply. Separately, embryo transfer and IVF/ICSI fertilisation are restricted procedures: the patient must be legally married to a man, and her husband must consent. This requirement does not override the separate prohibition in regulation 36(a). For a carrier aged 35 or younger, the medical-indication condition must be assessed in relation to the procedure on her; do not assume the intended parents’ infertility alone satisfies that wording. The marriage and husband-consent conditions apply to the carrier as the patient for transfer, not only to the intended mother.
If the patient is 45 or older
If a patient is, or is likely to be, over 45 when pregnancy starts, regulation 32 requires the licensee to have a process under which a qualified practitioner assesses her fitness to carry a pregnancy, give birth and care for the child, and provides appropriate clinical management and medical advice. Separately, a patient aged 45 or older on the day of an assisted-reproduction procedure must receive the information listed in regulation 25 at least 7 calendar days before written consent is given. These are different triggers: one is linked to age at the start of pregnancy, the other to age on the procedure date.
Whose eggs and sperm may be used
Regulation 37 limits embryo transfer using donor material. An embryo generally must be created from an oocyte collected from the patient and sperm collected from her husband. The regulations provide exceptions where the patient cannot produce any viable oocytes, has had at least one unsuccessful attempt to collect viable oocytes, or a qualified practitioner considers the likelihood of a foetus without a significant health condition or disability developing from her oocytes to be low. The husband’s sperm rule has corresponding exceptions where he cannot produce viable sperm or the practitioner considers the likelihood of a foetus without a significant health condition or disability from his sperm to be low. An embryo created from prohibited close-relative combinations cannot be transferred. These are statutory conditions, not simply a clinic’s preference. For gestational surrogacy, this is a separate potential barrier: the carrier is ordinarily the patient, so an embryo made from the intended parents’ gametes will not meet the default patient/husband-gamete rule unless a specified exception applies to the carrier and her husband. The exceptions are not a general authorisation to use donor gametes because the intended parents want a carrier. MOH’s official FAQ also says donor reproductive cells must not be used for social reasons or personal preferences; where viable gametes can be obtained but exceptional clinical circumstances may justify a donor embryo, the clinic may submit the case to MOH for review. Obtain written advice from the clinic and Singapore counsel identifying the exact exception relied on.
Donor age and selection criteria
Where donor reproductive cells or a donor embryo are used, regulation 37 requires documented criteria for donor selection and acceptance. Donor sperm may be accepted only from a man aged at least 21 but under 41; donor oocytes may be accepted only from a woman aged at least 21 but under 38. A donor embryo may be accepted only if it was created using an oocyte from a woman within that oocyte-donor age range. The limits concern the donor’s age when the cells are accepted under the rule, so a donor who has reached the upper boundary does not qualify. Ask the clinic to confirm the donor’s age eligibility in writing, rather than relying on a marketing description.
Medical assessment of donors
Before accepting a reproductive cell or embryo, the licensee must operate a system for assessing every donor’s medical fitness and suitability. At minimum, regulation 39 requires a clinical evaluation and review of the donor’s medical history by a qualified assisted-reproduction practitioner. The donor must also sign a written declaration, to the best of their knowledge, covering medical history and whether they have engaged in behaviour carrying a high risk of communicable disease, including drug use and unprotected sex with multiple partners. This is a mandatory minimum. The provision does not itself list one universal genetic-test panel or make every possible family-history issue an automatic exclusion; the provider’s documented criteria and the individual clinical assessment matter.
Infection testing and timing
Regulation 47 names four specified pathogens: HIV, hepatitis B virus, hepatitis C virus and Treponema pallidum, the bacterium associated with syphilis. Before collecting or receiving a reproductive cell from a patient, her husband or a donor, or storing a collected reproductive cell, the licensee must ensure that the relevant person was tested for each specified pathogen within the preceding 6 months. A reproductive-cell donor must also be tested for HIV immediately before collection and again after at least 3 months. If the recipient intends to use the donor’s cells before that second HIV test, the donor is treated as HIV-positive for the purposes of the regulation’s disclosure and storage safeguards. The clinic must explain the risk, obtain the required written acknowledgements and consent, and minimise cross-contamination risk in storage. Ask for the dates and scope of tests, not merely confirmation that “screening was done”. Separately, MOH’s official FAQ says clinics should screen donors and recipients using donor gametes or embryos for cytomegalovirus (CMV); rubella screening for the patient and risk-based thalassaemia screening may also apply. These are separate official-guidance/clinical requirements, not part of the four-pathogen list in regulation 47. Ask which additional tests apply and whether overseas results are acceptable.
The five-live-birth limit
Regulation 38(2) generally bars transfer of an embryo created from a donor’s reproductive cell if that donor’s cells have already resulted in at least 5 live-birth events. There is a narrow written-approval route: the Clinical Governance Officer may approve a further transfer only where an embryo from the same donor was previously transferred to the same patient and resulted in a live-birth event, and the patient has requested the further transfer. This is not a general waiver for a sixth unrelated recipient. Before treatment, ask the clinic to confirm that the donor’s previous live-birth events have been checked and that any required approval exists.
Consent and counselling
Regulation 25 requires written consent from the patient before an assisted-reproduction procedure and, except for elective oocyte storage, from her husband as well. Consent must be given within the 3 months before the procedure. Before consent, the provider must explain relevant examinations and treatment, estimated success rates, possible consequences and side effects, the number of embryos to be transferred, plans for stored cells or embryos, and additional risks linked to age or previous stimulated cycles. For a donor, regulation 27 requires written consent for collection or transfer; the donor must receive information at least 7 calendar days before consent, including intended uses, suitability tests and relevant consequences of oocyte collection. Consent must be voluntary, signed and properly witnessed. It should not be obtained by coercion, deception or improper inducement. Consent may generally be withdrawn before a reproductive cell or embryo is used if the person informs the licensee. The rule has exceptions where the material was stored anonymously in accordance with consent or is no longer in the licensee’s custody; ask how any withdrawal is recorded and applied.
Donor identity and directed donations
A licensee must not disclose a donor’s identity except where disclosure is required by written law, authorised or required by a court order, or consented to by the donor or the donor’s legal representative. Confidentiality is therefore a rule with defined exceptions, not an absolute promise that identity can never be revealed. A directed donation to a named recipient has a further rule: the clinic cannot use the cells or embryo for that recipient unless the donor has consented to disclosure of the donor’s identity to that recipient. If a donor material is intended for a particular person, document the identity-disclosure consent and any restrictions on alternative uses before transfer or storage.
Imported material and payment
A Singapore licensee may transfer reproductive cells or embryos only to, or receive them from, another authorised licensee or a person in a foreign jurisdiction who is legally permitted there to provide the relevant service or operate a reproductive-cell or embryo bank. Transfer is also subject to written consent and the local rules on donor eligibility, screening and risk disclosure. For material originating outside Singapore, the clinic must explain the risks of using it. Separately, section 13 of the Human Cloning and Other Prohibited Practices Act 2004 prohibits commercial trading in human eggs, sperm and embryos; official licence conditions recognise only reasonable expenses, not an unrestricted market price. Do not assume a fee is permitted because an intermediary calls it compensation. Request an itemised explanation and legal review.
Other clinical limits
The regulations contain safeguards beyond donor eligibility. A licensee must have procedures to reduce ovarian hyperstimulation syndrome, identify and manage patients at risk, monitor its incidence and document preventive steps. Ordinarily, no more than 2 embryos may be transferred in one cycle. Up to 3 cleavage-stage embryos may be transferred only where the patient is at least 37 and has had a stimulated cycle in which no oocytes were collected or none resulted in a blastocyst. Sex selection is prohibited unless a qualified practitioner assesses a clinical need; mitochondrial replacement therapy is also prohibited. These limits do not make surrogacy permissible: each must be read alongside regulation 36(a) and the other eligibility rules. MOH licence conditions also require prior written approval from the Director-General of Health before transfer of a sex-revealed embryo; a clinical-need assessment alone is not that approval.
Binding law versus clinic policy
A useful distinction is between a legal floor and a clinic’s own clinical protocol. The regulations expressly set donor age limits, required medical-history review and declarations, specified pathogen tests and timing, consent procedures, restrictions on embryo transfer, and a donor-use limit. A clinic may apply additional documented medical or genetic screening, exclude a donor for a particular risk, or require extra records as part of safe practice. Such a protocol can be stricter than the statutory minimum; it should not be misrepresented as a universal statutory rule. Ask the provider to separate, in writing, each legal requirement, its own policy, the clinical reason for the policy and any point that remains uncertain.
Before proceeding: a practical checklist
Before paying or beginning treatment, obtain: (1) the clinic’s current Singapore assisted-reproduction licence details; (2) a written explanation of how it addresses regulation 36(a) in the exact proposed surrogacy arrangement; (3) the practitioner’s assessment of the patient’s medical fitness and applicable age conditions; (4) the basis for using any donor oocyte, sperm or embryo under regulation 37; (5) the donor’s age eligibility and the clinic’s documented selection criteria; (6) dated results for HIV, hepatitis B, hepatitis C and syphilis testing, including the repeat HIV test where applicable; (7) confirmation of the donor’s previous live-birth count and any written approval needed; (8) signed consent documents and an explanation of withdrawal, storage and disclosure terms; and (9) an itemised breakdown of donor-related expenses. Keep copies. If the clinic cannot explain the legal basis, pause the procedure and obtain independent Singapore legal advice. For a carrier, specifically request a written explanation of how regulations 31 and 37 apply to her: age/medical indication, marriage and husband’s consent, gamete source, and the precise exception the clinic relies on.
How the rules work in practice
Example 1: a donor is 40. That donor may meet the sperm-donor age rule, but only if the other selection, evaluation and testing requirements are also met; age alone is not approval. Example 2: a donor’s sperm was collected today and the recipient wants to use it before the follow-up HIV test at least 3 months later. The special deemed-positive rule applies, triggering risk explanation, written consent and protective storage measures. Example 3: a carrier agrees to transfer an embryo and then hand the child to intended parents. Even if her health and gamete criteria are met, regulation 36(a) remains a separate obstacle that must be addressed before transfer. The right sequence is legal feasibility first, clinical eligibility and screening second, consent and logistics after that. Even if the carrier is medically fit, her age/medical-indication and marital-status conditions and regulation 37’s gamete-source rule must be checked independently; regulation 36(a) may be an additional issue depending on the planned post-birth legal route.
Primary sources
- Healthcare Services (Assisted Reproduction Service) Regulations 2023 — Singapore Statutes Online
- Assisted Reproduction Service — Healthcare Services Act (HCSA), Singapore
- Human Cloning and Other Prohibited Practices Act 2004 — Singapore Statutes Online
- Licence Conditions for Assisted Reproduction Services — Ministry of Health, Singapore
- Healthcare Services (Assisted Reproduction Service) Regulations — Official FAQ, Ministry of Health, Singapore (updated 13 January 2026)
Verify current law and the specific facts before relying on it.
